Telix Pharmaceuticals Ltd (ASX: TLX) shares have dipped on Friday after news broke that several law firms had filed class actions against the company in the US.
Law firm Robbins Geller Rudman and Dowd was among the law firms that filed a claim and encouraged shareholders to join their push for damages.
Claims the company made false statements
That firm's claim, Thomas v. Telix Pharmaceuticals Ltd, alleges the company and certain of its executives breached the US Securities Exchange Act of 1934 during the period 21 February 2025 through to 28 August 2025.
The law firm says on its website:
The Telix Pharmaceuticals class action lawsuit alleges that throughout the class period defendants made false and/or misleading statement and/or failed to disclose that: (i) defendants materially overstated the progress Telix Pharmaceuticals had made with regard to prostate cancer therapeutic candidates; and (ii) defendants materially overstated the quality of Telix Pharmaceuticals' supply chain and partners.
The suit further alleges that on 22 July 2025, the company "received a subpoena from the U.S. Securities and Exchange Commission (SEC) seeking various documents and information primarily relating to the Company's disclosures regarding the development of the Company's prostate cancer therapeutics candidates".
The law firm says the company's shares, which are also listed in the US, subsequently fell more than 13% across two trading days.
Then later on 28 August, the claim says Telix "disclosed that it received a Complete Response Letter from the U.S. Food and Drug Administration ("FDA") for the Biologics License Application for its product TLX250-CDx, which identified "\'deficiencies relating to the Chemistry, Manufacturing, and Controls (CMC) package"'.
The FDA additionally 'documented notices of deficiency (Form 483) issued to two third-party manufacturing and supply chain partners that will require remediation prior to resubmission,' according to the complaint. The Telix Pharmaceuticals class action lawsuit alleges that on this news, the price of Telix Pharmaceuticals ADSs fell more than 21% over two trading sessions.
Other law firms that have lodged similar actions include Hagens Berman Shareholder Advocates and Berger Montague.
Telix is yet to make a statement to the ASX regarding the lawsuits.
Telix shares were trading 4.3% lower on Friday at $14.34. The shares have traded as high as $31.97 over the past year.
Telix in mid-October reported third-quarter revenue of about $206 million, up 53% on the same period the previous year and upgraded its full-year revenue guidance to $800 to $820 million.
The company was valued at $5.07 billion at the close of trade on Thursday. Telix has been contacted for comment.
Bell Potter recently said it had a $23 price target on Telix shares.
